ClinicalTrials.gg
Active, not recruitingNCT02542293NEPTUNEUpdated Aug 6, 2026Results posted

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

A Phase 3 interventional study of Durvalumab +Tremelimumab and Paclitaxel + carboplatin in Non Small Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca. Active, not recruiting at 210 sites in 29 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
953
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 94
953 · median 74
Started
2015
with 6 others
Phase 3
17 of 94
3 open now
Primary completion
2020-09
later than 2 of 36 live
Registered
13th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 7 that started in 2015, is one of 17 in phase 3, reaches primary completion later than 2 of the 36 other live ones, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.

Read the detailed description

Patients will be randomized in a 1:1 to receive treatment with durvalumab + tremelimumab combination therapy or SoC therapy. The primary objective of this study is to assess the efficacy of combination treatment compared with SoC in terms of Overall Survival (OS) in patients.

03

Conditions studied

  • Non Small Cell Lung Carcinoma NSCLC

Keywords

  • NSCLC
  • PDL1
  • TMB
  • MEDI4736
  • Durvalumab
  • Tremelimumab
  • OS
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study, patients should fulfill the following criteria:

  • Aged at least 18 years
  • Documented evidence of Stage IV NSCLC
  • No activating EGFR mutation or ALK rearrangement
  • No prior chemotherapy or any other systemic therapy for recurrent/ NSCLC
  • World Health Organization (WHO) Performance Status of 0 or 1
  • No Prior exposure to Immune Mediated Therapy (IMT), including, but not limited to, other antiCTLA4, antiPD1, anti PDL1,or antiPDL2 antibodies, excluding therapeutic anticancer vaccines

Exclusion criteria

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  • Mixed small cell lung cancer and NSCLC histology, sarcomatoid variant
  • or spinal cord compression unless the patient is stable (asymptomatic; no evidence of new or emerging brain metastases) and off for at least 14 days prior to start of study treatment.
  • Active or prior documented or inflammatory disorders (e.g., Crohn's disease, ulcerative colitis)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
953 participants (actual)

Study arms

  • Experimental
    Combination Therapy

    Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)

    Biological: Durvalumab +Tremelimumab

  • Active comparator
    Standard of Care

    Standard of Care chemotherapy treatment

    Drug: Paclitaxel + carboplatin · Drug: Gemcitabine + cisplatin · Drug: Gemcitabine + carboplatin · Drug: Pemetrexed + cisplatin · Drug: Pemetrexed + carboplatin

Interventions

  • BiologicalDurvalumab +Tremelimumab

    Drug pages: Durvalumab · Tremelimumab

  • DrugPaclitaxel + carboplatin

    Drug pages: Paclitaxel · Carboplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugGemcitabine + cisplatin

    Drug pages: Gemcitabine · Cisplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugGemcitabine + carboplatin

    Drug pages: Gemcitabine · Carboplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugPemetrexed + cisplatin

    Drug pages: Pemetrexed · Cisplatin

    Chemotherapy Agent

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugPemetrexed + carboplatin

    Drug pages: Pemetrexed · Carboplatin

    Chemotherapy Agent

    Also known as: Platinum based Standard of Care Chemotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).

  2. OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the China cohort DCO date (a maximum of approximately 44 months).

Secondary outcomes

  1. OS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets

    OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at time of analysis was censored based on last recorded date on which participant was known to be alive. bTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb and bTMB \<20 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥16 mut/Mb, ≥12 mut/Mb and \<20 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). bTMB non-evaluable analysis set included the subset of participants in FAS whose bTMB status at baseline could not be determined by the GuardantOMNI CDx assay or whose sample was not available. tTMB analysis sets are defined same as the bTMB analysis sets.

    Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).

  2. OS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets

    The OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on last recorded date on which participant was known to be alive. Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.

    Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global or China cohort DCO dates, as applicable (a maximum of approximately 44 months) for each cohort.

  3. Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets

    The PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \[RECIST 1.1\] using Investigator assessments) was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

    Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).

  4. PFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets

    PFS (per RECIST 1.1 using Investigator assessments) was defined as time from date of randomization until date of objective PD or death regardless of whether participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). PD-L1-negative analysis set included subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: FAS included all randomized participants prior to end of global recruitment. China Cohort: China FAS included all randomized participants in China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included subset of participants in FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.

    Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.

  5. Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets

    The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) prior to PD. bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

    Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).

  6. ORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets

    The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD. PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.

    Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.

  7. Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets

    DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

    Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).

  8. DoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets

    DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

    Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.

  9. Alive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets

    The APF12 was defined as the percentage of participants who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.

  10. APF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets

    The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.

  11. Time From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets

    The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

    Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).

  12. PFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets

    The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

    Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.

  13. OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

    Time frame: Months 12, 18 and 24

  14. OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

    Time frame: Months 12, 18 and 24

  15. Serum Concentrations of Durvalumab

    Blood samples were collected to determine the serum concentration of durvalumab.

    Time frame: Pre-dose and within 1 hour after end of infusion at Week 0 and 12; pre-dose on Week 24 and at follow-up Month 3

  16. Serum Concentrations of Tremelimumab

    Blood samples were collected to determine the serum concentration of tremelimumab.

    Time frame: Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3

  17. Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab

    Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

    Time frame: At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.

  18. Number of Participants With ADA Response to Tremelimumab

    Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

    Time frame: At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.

07

Results

Posted May 24, 2022
Limitations and caveats
Analysis of the China cohort was performed to evaluate the consistency of efficacy and safety in Chinese participants with the global cohort in order to meet China health regulatory requirements and was not powered for a formal assessment of statistical significance.

Participant flow

A total of 192 centers across 29 countries in North America, Latin America, Asia, Europe and Gulf countries randomized adults with epidermal growth factor receptor and anaplastic lymphoma kinase wild-type advanced or metastatic non-small-cell lung cancer (NSCLC) in this study. First participant was enrolled on 03 November 2015 and final data cut-off (DCO) date was 24 June 2019 for Global cohort and 21 September 2020 for China cohort. SoC = standard of care

Participant flow — Overall Study
MilestoneAll Participants: Durvalumab + TremelimumabAll Participants: SoC Chemotherapy
Started474479
Randomized in global cohort410413
Received treatment in global cohort410399
Randomized in china cohort7882
Received treatment in china cohort7778
Included in both cohorts (global and china)1416
Ongoing in study at dco for final analysis in global cohort7567
Ongoing in study at dco for final analysis in china cohort2718
Completed9983
Not completed375396
Withdrew: Death367377
Withdrew: Withdrawal by subject819

Outcome measures

PrimaryOverall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).
Reported as:
Median · months
Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set
monthsGlobal: Durvalumab + TremelimumabGlobal: SoC Chemotherapy
Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set11.7 (8.6 to 15.2)9.1 (7.8 to 12.6)
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Log Rank · p = 0.0808 (The 2-sided p-value was calculated using an unstratified log-rank test.) · Hazard ratio (hr): 0.71 · 95% CI 0.485 to 1.045The HR and confidence interval (CI) were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
PrimaryOS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the China cohort DCO date (a maximum of approximately 44 months).
Reported as:
Median · months
OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set
monthsChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set15.0 (10.5 to 27.4)11.7 (8.6 to 20.5)
Statistical analysis
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.60 · 95% CI 0.322 to 1.109The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach.
SecondaryOS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets

OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at time of analysis was censored based on last recorded date on which participant was known to be alive. bTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb and bTMB \<20 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥16 mut/Mb, ≥12 mut/Mb and \<20 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). bTMB non-evaluable analysis set included the subset of participants in FAS whose bTMB status at baseline could not be determined by the GuardantOMNI CDx assay or whose sample was not available. tTMB analysis sets are defined same as the bTMB analysis sets.

Time frame:
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).
Reported as:
Median · months
OS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
monthsGlobal: Durvalumab + TremelimumabGlobal: SoC Chemotherapy
bTMB ≥16 mut/Mb analysis set12.1 (8.6 to 15.0)11.9 (8.5 to 15.9)
bTMB ≥12 mut/Mb analysis set10.9 (8.6 to 12.6)10.3 (8.3 to 12.9)
PD-L1 negative analysis set11.1 (8.1 to 14.7)12.5 (9.9 to 16.2)
bTMB <20 mut/Mb analysis set9.9 (7.7 to 12.8)11.5 (8.8 to 13.7)
bTMB non-evaluable analysis set9.3 (7.2 to 15.5)10.4 (9.4 to 13.8)
tTMB ≥14 mut/Mb analysis set17.5 (9.8 to NA)10.6 (7.0 to 20.9)
tTMB ≥12 mut/Mb analysis set11.1 (7.0 to 17.5)13.9 (9.0 to 17.9)
tTMB ≥10 mut/Mb analysis set11.1 (7.2 to 15.7)10.6 (9.0 to 15.7)
tTMB ≥8 mut/Mb analysis set11.0 (7.8 to 15.7)10.2 (8.0 to 13.5)
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.87 · 95% CI 0.629 to 1.201The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.94 · 95% CI 0.726 to 1.213The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 1.07 · 95% CI 0.786 to 1.464The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 1.04 · 95% CI 0.835 to 1.302The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 1.01 · 95% CI 0.758 to 1.353The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.57 · 95% CI 0.309 to 1.008The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.87 · 95% CI 0.560 to 1.350The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.88 · 95% CI 0.614 to 1.251The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.78 · 95% CI 0.564 to 1.080The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
SecondaryOS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets

The OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on last recorded date on which participant was known to be alive. Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.

Time frame:
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global or China cohort DCO dates, as applicable (a maximum of approximately 44 months) for each cohort.
Reported as:
Median · months
OS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets
monthsGlobal: Durvalumab + TremelimumabGlobal: SoC ChemotherapyChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
FAS10.9 (9.3 to 12.6)12.1 (10.3 to 13.5)20.0 (15.0 to 28.7)14.1 (9.5 to 19.4)
PD-L1 TC ≥25% analysis set12.2 (9.7 to 15.2)10.4 (8.6 to 12.2)36.6 (15.5 to NA)15.8 (9.0 to 26.9)
PD-L1 TC ≥50% analysis set14.1 (10.0 to 19.3)10.5 (8.7 to 12.6)36.6 (16.9 to NA)15.8 (9.0 to 26.9)
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 1.02 · 95% CI 0.871 to 1.186The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (≥25% Vs \<25%), smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.70 · 95% CI 0.480 to 1.018The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>= 25% Vs \< 25 and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.84 · 95% CI 0.654 to 1.078The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.56 · 95% CI 0.289 to 1.065The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.80 · 95% CI 0.587 to 1.081The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.47 · 95% CI 0.222 to 0.955The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach.
SecondaryProgression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets

The PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \[RECIST 1.1\] using Investigator assessments) was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

Time frame:
Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).
Reported as:
Median · months
Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
monthsGlobal: Durvalumab + TremelimumabGlobal: SoC Chemotherapy
bTMB ≥20 mut/Mb analysis set4.2 (2.7 to 5.6)5.1 (4.2 to 5.6)
bTMB ≥16 mut/Mb analysis set4.2 (2.8 to 5.5)5.5 (4.4 to 5.8)
bTMB ≥12 mut/Mb analysis set3.9 (2.8 to 4.8)5.1 (4.4 to 5.6)
tTMB ≥14 mut/Mb analysis set8.7 (5.2 to 22.3)5.8 (4.4 to 7.9)
tTMB ≥12 mut/Mb analysis set5.2 (3.8 to 6.9)5.8 (4.2 to 6.6)
tTMB ≥10 mut/Mb analysis set4.3 (2.8 to 5.5)5.1 (4.2 to 5.8)
tTMB ≥8 mut/Mb analysis set4.4 (2.9 to 5.5)5.0 (4.2 to 5.6)
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.77 · 95% CI 0.514 to 1.146The HR and CI interval were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.86 · 95% CI 0.623 to 1.189The HR and CI interval were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.92 · 95% CI 0.714 to 1.193The HR and CI interval were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.46 · 95% CI 0.258 to 0.818The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.80 · 95% CI 0.524 to 1.228The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.83 · 95% CI 0.585 to 1.177The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.74 · 95% CI 0.534 to 1.017The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
SecondaryPFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets

PFS (per RECIST 1.1 using Investigator assessments) was defined as time from date of randomization until date of objective PD or death regardless of whether participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). PD-L1-negative analysis set included subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: FAS included all randomized participants prior to end of global recruitment. China Cohort: China FAS included all randomized participants in China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included subset of participants in FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.

Time frame:
Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.
Reported as:
Median · months
PFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets
monthsGlobal: Durvalumab + TremelimumabGlobal: SoC ChemotherapyChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
PD-L1-negative NSCLC analysis set4.1 (2.8 to 5.2)5.6 (4.6 to 6.0)5.1 (2.8 to 7.2)6.0 (4.0 to 7.5)
FAS4.0 (2.9 to 4.2)5.6 (5.3 to 5.7)4.2 (2.8 to 7.2)6.0 (5.5 to 7.5)
PD-L1 TC ≥25% analysis set4.2 (3.2 to 5.7)5.4 (4.4 to 5.6)6.8 (4.1 to 8.4)5.7 (4.2 to 8.5)
PD-L1 TC ≥50% analysis set4.6 (3.1 to 6.0)5.4 (4.3 to 5.6)6.8 (4.2 to 20.2)5.7 (4.2 to 8.5)
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 1.11 · 95% CI 0.810 to 1.517The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 1.13 · 95% CI 0.592 to 2.141The HR and CI interval were calculated using an stratified Cox proportional hazards model, adjusting histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 1.08 · 95% CI 0.924 to 1.253The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (≥25% Vs \<25%), smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.95 · 95% CI 0.655 to 1.362The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (≥ 25% Vs \< 25%) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.80 · 95% CI 0.621 to 1.024The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.72 · 95% CI 0.389 to 1.317The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.74 · 95% CI 0.542 to 1.010The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.65 · 95% CI 0.335 to 1.251The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach.
SecondaryObjective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets

The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) prior to PD. bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

Time frame:
Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).
Reported as:
Number · percentage of participants
Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
percentage of participantsGlobal: Durvalumab + TremelimumabGlobal: SoC Chemotherapy
bTMB ≥20 mut/Mb analysis set27.543.3
bTMB ≥16 mut/Mb analysis set31.246.1
bTMB ≥12 mut/Mb analysis set28.742.0
tTMB ≥14 mut/Mb analysis set61.344.7
tTMB ≥12 mut/Mb analysis set42.641.8
tTMB ≥10 mut/Mb analysis set37.742.5
tTMB ≥8 mut/Mb analysis set36.741.2
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 0.50 · 95% CI 0.236 to 1.030
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 0.53 · 95% CI 0.288 to 0.968
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 0.55 · 95% CI 0.336 to 0.908
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 1.96 · 95% CI 0.752 to 5.234
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 1.03 · 95% CI 0.482 to 2.214
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 0.82 · 95% CI 0.430 to 1.548
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 0.83 · 95% CI 0.456 to 1.486
SecondaryORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets

The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD. PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.

Time frame:
Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.
Reported as:
Number · percentage of participants
ORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets
percentage of participantsGlobal: Durvalumab + TremelimumabGlobal: SoC ChemotherapyChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
PD-L1-negative NSCLC analysis set23.138.823.141.4
FAS25.941.735.939.0
PD-L1 TC ≥25% analysis set35.243.954.840.6
PD-L1 TC ≥50% analysis set37.444.060.046.4
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 0.47 · 95% CI 0.245 to 0.869The analysis was performed using logistic regression, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Binomial exact test · Odds ratio (or): 0.42 · 95% CI 0.124 to 1.337
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 0.48 · 95% CI 0.356 to 0.647The analysis was performed using logistic regression adjusting for PD-L1 status (≥25% Vs \<25%), smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Odds ratio (or): 0.87 · 95% CI 0.450 to 1.660The analysis was performed using logistic regression, adjusting for PD-L1 status (\>= 25% Vs \< 25%), smoking status (never smoker Va ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 0.69 · 95% CI 0.443 to 1.079The analysis was performed using logistic regression, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Odds ratio (or): 1.78 · 95% CI 0.658 to 4.919The analysis was performed using logistic regression, adjusting for PD-L1 status (\>= 25% Vs \< 25%), smoking status (never smoker Va ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Odds ratio (or): 0.76 · 95% CI 0.449 to 1.291The analysis was performed using logistic regression, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Odds ratio (or): 1.73 · 95% CI 0.585 to 5.270The analysis was performed using logistic regression, adjusting for PD-L1 status (\>= 25% Vs \< 25%), smoking status (never smoker Va ever smoker) and histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
SecondaryDuration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets

DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

Time frame:
Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).
Reported as:
Median · months
Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
monthsGlobal: Durvalumab + TremelimumabGlobal: SoC Chemotherapy
bTMB ≥20 mut/Mb analysis set11.6 (6.7 to 21.5)4.2 (3.0 to 6.9)
bTMB ≥16 mut/Mb analysis set10.6 (4.2 to 21.5)4.3 (3.0 to 5.9)
bTMB ≥12 mut/Mb analysis set11.5 (6.7 to 18.8)4.3 (3.0 to 5.6)
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.25 · 95% CI 0.113 to 0.532The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.36 · 95% CI 0.196 to 0.639The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.38 · 95% CI 0.233 to 0.611The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
SecondaryDoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets

DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

Time frame:
Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.
Reported as:
Median · months
DoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
monthsGlobal: Durvalumab + TremelimumabGlobal: SoC ChemotherapyChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
PD-L1-negative NSCLC analysis set10.2 (2.8 to 18.8)4.9 (4.2 to 6.1)10.5 (1.4 to NA)6.1 (3.0 to 11.7)
FAS11.1 (6.9 to 15.2)4.9 (4.2 to 5.6)12.9 (5.4 to 33.6)6.1 (4.4 to 7.2)
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.41 · 95% CI 0.199 to 0.787The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.79 · 95% CI 0.183 to 2.860The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.44 · 95% CI 0.324 to 0.588The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.39 · 95% CI 0.193 to 0.761The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>= 25% Vs \< 25%) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
SecondaryAlive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets

The APF12 was defined as the percentage of participants who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 12 months.
Reported as:
Number · percentage of participants
Alive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
percentage of participantsGlobal: Durvalumab + TremelimumabGlobal: SoC Chemotherapy
bTMB ≥20 mut/Mb analysis set25.6 (15.7 to 36.6)7.0 (1.9 to 16.8)
bTMB ≥16 mut/Mb analysis set22.0 (14.1 to 31.1)12.3 (6.1 to 20.8)
bTMB ≥12 mut/Mb analysis set21.6 (15.2 to 28.9)13.8 (8.3 to 20.6)
SecondaryAPF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets

The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 12 months.
Reported as:
Number · percentage of participants
APF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
percentage of participantsGlobal: Durvalumab + TremelimumabGlobal: SoC ChemotherapyChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
PD-L1-negative NSCLC analysis set18.2 (10.9 to 26.9)12.1 (6.3 to 19.9)15.6 (4.0 to 34.4)11.3 (2.3 to 28.5)
FAS20.2 (16.4 to 24.3)14.9 (11.4 to 18.9)23.9 (14.8 to 34.2)16.6 (8.5 to 27.0)
SecondaryTime From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets

The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

Time frame:
Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).
Reported as:
Median · months
Time From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
monthsGlobal: Durvalumab + TremelimumabGlobal: SoC Chemotherapy
bTMB ≥20 mut/Mb analysis set10.6 (8.5 to 14.4)8.6 (7.3 to 12.6)
bTMB ≥16 mut/Mb analysis set10.9 (8.5 to 14.1)10.5 (8.0 to 13.2)
bTMB ≥12 mut/Mb analysis set9.9 (8.2 to 11.7)9.0 (7.8 to 10.8)
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.72 · 95% CI 0.494 to 1.058The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.84 · 95% CI 0.607 to 1.151The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.89 · 95% CI 0.689 to 1.146The HR and CI were calculated using an unstratified Cox proportional hazards model, with ties handled by the Efron approach.
SecondaryPFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets

The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

Time frame:
Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.
Reported as:
Median · months
PFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
monthsGlobal: Durvalumab + TremelimumabGlobal: SoC ChemotherapyChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
PD-L1-negative NSCLC analysis set9.1 (6.9 to 12.8)12.4 (8.8 to 14.9)13.8 (10.1 to 27.4)10.3 (6.5 to 14.1)
FAS9.4 (8.2 to 10.9)10.4 (9.1 to 11.5)15.5 (12.5 to 24.5)12.9 (9.2 to 15.4)
Statistical analysis
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 1.02 · 95% CI 0.748 to 1.388The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.67 · 95% CI 0.360 to 1.219The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach.
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy · Hazard ratio (hr): 0.98 · 95% CI 0.845 to 1.147The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>= 25% Vs \< 25%), smoking status (never smoker Vs ever smoker) and histology (squamous Vs non-squamous), with ties handled by Efron approach.
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy · Hazard ratio (hr): 0.71 · 95% CI 0.492 to 1.030The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Efron approach.
SecondaryOS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

Time frame:
Months 12, 18 and 24
Reported as:
Number · percentage of participants
OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
percentage of participantsGlobal: Durvalumab + TremelimumabGlobal: SoC Chemotherapy
Month 12: bTMB ≥20 mut/Mb analysis set49.3 (37.1 to 60.4)40.8 (28.3 to 52.9)
Month 12: bTMB ≥16 mut/Mb analysis set50.5 (40.0 to 60.2)48.9 (38.2 to 58.8)
Month 12: bTMB ≥12 mut/Mb analysis set46.9 (38.5 to 54.8)44.6 (36.1 to 52.7)
Month 18: bTMB ≥20 mut/Mb analysis set36.2 (25.1 to 47.4)20.4 (11.3 to 31.4)
Month 18: bTMB ≥16 mut/Mb analysis set35.5 (25.9 to 45.1)28.5 (19.5 to 38.1)
Month 18: bTMB ≥12 mut/Mb analysis set29.4 (22.1 to 36.9)27.8 (20.6 to 35.4)
Month 24: bTMB ≥20 mut/Mb analysis set26.1 (16.4 to 36.8)13.6 (6.4 to 23.6)
Month 24: bTMB ≥16 mut/Mb analysis set24.0 (15.8 to 33.2)18.2 (11.0 to 26.9)
Month 24: bTMB ≥12 mut/Mb analysis set21.3 (15.0 to 28.4)19.0 (12.9 to 26.0)
SecondaryOS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

Time frame:
Months 12, 18 and 24
Reported as:
Number · percentage of participants
OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
percentage of participantsGlobal: Durvalumab + TremelimumabGlobal: SoC ChemotherapyChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
Month 12: PD-L1-negative NSCLC analysis set47.8 (37.2 to 57.6)52.8 (42.6 to 61.9)68.0 (46.1 to 82.5)46.4 (27.6 to 63.3)
Month 12: FAS47.7 (42.8 to 52.5)50.0 (45.0 to 54.8)72.8 (61.3 to 81.3)53.1 (41.7 to 63.2)
Month 18: PD-L1-negative NSCLC analysis set34.1 (24.5 to 43.9)34.5 (25.4 to 43.8)44.0 (24.5 to 61.9)39.3 (21.7 to 56.5)
Month 18: FAS34.8 (30.2 to 39.5)34.6 (30.0 to 39.3)54.6 (42.8 to 64.9)41.8 (31.0 to 52.3)
Month 24: PD-L1-negative NSCLC analysis set22.1 (14.0 to 31.3)22.3 (14.7 to 30.9)36.0 (18.2 to 54.2)17.9 (6.5 to 33.7)
Month 24: FAS25.7 (21.6 to 30.1)23.4 (19.4 to 27.7)44.2 (32.9 to 54.8)30.4 (20.7 to 40.6)
SecondarySerum Concentrations of Durvalumab

Blood samples were collected to determine the serum concentration of durvalumab.

Time frame:
Pre-dose and within 1 hour after end of infusion at Week 0 and 12; pre-dose on Week 24 and at follow-up Month 3
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Serum Concentrations of Durvalumab
microgram per milliliter (µg/mL)Global: Durvalumab + TremelimumabChina: Durvalumab + Tremelimumab
Week 0: Pre-infusionNA ± NANA ± NA
Week 0: End of infusion418.6 ± 74.8392.7 ± 48.9
Week 12: Pre-infusion77.5 ± 138.172.4 ± 55.0
Week 12: End of infusion434.3 ± 105.6448.9 ± 40.0
Week 24: Pre-infusion108.8 ± 95.785.6 ± 93.9
Follow-up Month 38.8 ± 253.95.4 ± 351.7
SecondarySerum Concentrations of Tremelimumab

Blood samples were collected to determine the serum concentration of tremelimumab.

Time frame:
Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3
Reported as:
Geometric mean · µg/mL
Serum Concentrations of Tremelimumab
µg/mLGlobal: Durvalumab + TremelimumabChina: Durvalumab + Tremelimumab
Week 0: Pre-infusionNA ± NANA ± NA
Week 0: End of infusion20.3 ± 38.718.4 ± 43.3
Week 12: Pre-infusion3.4 ± 99.63.3 ± 64.6
Week 12: End of infusion20.8 ± 67.423.2 ± 43.4
Follow-up Month 3NA ± NANA ± NA
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab

Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

Time frame:
At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
ParticipantsGlobal: Durvalumab + TremelimumabChina: Durvalumab + Tremelimumab
ADA positive at any visit (ADA prevalence)261
Treatment-emergent ADA positive (ADA incidence)121
Treatment-boosted ADA00
Treatment-induced ADA (positive post-baseline only)121
ADA positive post-baseline and positive at baseline10
Persistent positive111
Transient positive20
nAb positive at any visit30
ADA positive at baseline and not detected post-baseline130
SecondaryNumber of Participants With ADA Response to Tremelimumab

Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

Time frame:
At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.
Reported as:
Count of participants · Participants
Number of Participants With ADA Response to Tremelimumab
ParticipantsGlobal: Durvalumab + TremelimumabChina: Durvalumab + Tremelimumab
ADA positive at any visit (ADA prevalence)492
Treatment-emergent ADA positive (ADA incidence)371
Treatment-boosted ADA10
Treatment-induced ADA (positive post-baseline only)361
ADA positive post-baseline and positive at baseline41
Persistent positive290
Transient positive112
nAb positive at any visit330
ADA positive at baseline and not detected post-baseline90

Adverse events

Collected over Assessed until final analysis DCO for each cohort (24 June 2019 for Global Cohort and 21 September 2020 for China Cohort); maximum timeframe of approximately 44 months for each cohort.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Global: Durvalumab + Tremelimumab328/410 (80%)193/410 (47.1%)310/410 (75.6%)
Global: SoC Chemotherapy329/413 (79.7%)112/399 (28.1%)349/399 (87.5%)
China: Durvalumab + Tremelimumab50/78 (64.1%)32/77 (41.6%)73/77 (94.8%)
China: SoC Chemotherapy62/82 (75.6%)22/78 (28.2%)77/78 (98.7%)
Most frequent serious events
Showing 10 of 230
Most frequent serious events
EventGlobal: Durvalumab + TremelimumabGlobal: SoC ChemotherapyChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
PneumoniaInfections and infestations27/41013/3993/775/78
Pleural effusionRespiratory, thoracic and mediastinal disorders5/4101/3994/772/78
PneumonitisRespiratory, thoracic and mediastinal disorders16/4100/3990/770/78
PyrexiaGeneral disorders12/4101/3993/770/78
DyspnoeaRespiratory, thoracic and mediastinal disorders5/4102/3993/771/78
Bone marrow failureBlood and lymphatic system disorders0/4101/3990/773/78
AnaemiaBlood and lymphatic system disorders0/41011/3990/772/78
HaemoptysisRespiratory, thoracic and mediastinal disorders2/4100/3992/770/78
Respiratory failureRespiratory, thoracic and mediastinal disorders1/4100/3992/770/78
RashSkin and subcutaneous tissue disorders0/4102/3992/770/78
Most frequent other events
Showing 10 of 69
Most frequent other events
EventGlobal: Durvalumab + TremelimumabGlobal: SoC ChemotherapyChina: Durvalumab + TremelimumabChina: SoC Chemotherapy
AnaemiaBlood and lymphatic system disorders59/410146/39925/7753/78
Neutrophil count decreasedInvestigations4/41029/3994/7735/78
White blood cell count decreasedInvestigations0/4100/3992/7735/78
NauseaGastrointestinal disorders57/410128/39910/7733/78
Aspartate aminotransferase increasedInvestigations27/41028/39925/7720/78
HypoalbuminaemiaMetabolism and nutrition disorders0/4100/39923/7715/78
Alanine aminotransferase increasedInvestigations33/41034/39922/7722/78
Decreased appetiteMetabolism and nutrition disorders69/41072/39914/7722/78
Amylase increasedInvestigations0/4100/39921/777/78
Gamma-glutamyltransferase increasedInvestigations0/4100/39919/7710/78

Baseline characteristics

Global Cohort: The full analysis set (FAS) included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. Participants included in both cohorts are not double-counted for the baseline characteristics analysis represented by 'All participants'.

Age, Customized
Age, Customized(Participants)All Participants: Durvalumab + TremelimumabAll Participants: SoC ChemotherapyTotal
All participants — <=18 years000
All participants — Between 18 and 65 years278244522
All participants — >=65 years196235431
Global cohort — <=18 years000
Global cohort — Between 18 and 65 years233203436
Global cohort — >=65 years177210387
China cohort — <=18 years000
China cohort — Between 18 and 65 years5351104
China cohort — >=65 years253156
Sex: Female, Male
Sex: Female, Male(Participants)All Participants: Durvalumab + TremelimumabAll Participants: SoC ChemotherapyTotal
All participants — Female127129256
All participants — Male347350697
Global cohort — Female113108221
Global cohort — Male297305602
China cohort — Female182543
China cohort — Male6057117
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants: Durvalumab + TremelimumabAll Participants: SoC ChemotherapyTotal
All participants — White307289596
All participants — Black or African American3710
All participants — Asian150165315
All participants — American Indian or Alaska Native101222
All participants — Other347
All participants — Missing123
Global cohort — White307289596
Global cohort — Black or African American3710
Global cohort — Asian8699185
Global cohort — American Indian or Alaska Native101222
Global cohort — Other347
Global cohort — Missing123
China cohort — White000
China cohort — Black or African American000
China cohort — Asian7882160
China cohort — American Indian or Alaska Native000
China cohort — Other000
China cohort — Missing000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants: Durvalumab + TremelimumabAll Participants: SoC ChemotherapyTotal
All participants — Hispanic or Latino504898
All participants — Not Hispanic or Latino423429852
All participants — Missing123
Global cohort — Hispanic or Latino504898
Global cohort — Not Hispanic or Latino359363722
Global cohort — Missing123
China cohort — Hispanic or Latino000
China cohort — Not Hispanic or Latino7882160
China cohort — Missing000
08

Study locations

210 sites
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Florham Park, New Jersey 07932, United States
  • Research Site
    Albuquerque, New Mexico 87102, United States
  • Research Site
    East Setauket, New York 11733, United States
  • Research Site
    Fresh Meadows, New York 11366, United States
  • Research Site
    Poughkeepsie, New York 12601, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Research Site
    Canton, Ohio 44710, United States
  • Research Site
    Columbus, Ohio 43219, United States
  • Research Site
    Zanesville, Ohio 43701, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Berazategui, B1884BBF, Argentina
  • Research Site
    CABA, C1426ANZ, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1025ABI, Argentina
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    La Rioja, 5300, Argentina
  • Research Site
    Rosario, S2000KZE, Argentina
  • Research Site
    San Salvador de Jujuy, 4600, Argentina
  • Research Site
    Santa Rosa, 6300, Argentina
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30110-022, Brazil
  • Research Site
    Belo Horizonte, 30380-472, Brazil
  • Research Site
    Fortaleza, 60336-045, Brazil
  • Research Site
    Ijuí, 98700-000, Brazil
  • Research Site
    Itajaí, 88301-220, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 90160-093, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01221-020, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01323 900, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Shumen, 9700, Bulgaria
  • Research Site
    Sofia, 1303, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Vratsa, 3000, Bulgaria
  • Research Site
    Santiago, 7500713, Chile
  • Research Site
    Santiago, 7500921, Chile
  • Research Site
    Santiago, 7520349, Chile
  • Research Site
    Santiago, 8380456, Chile
  • Research Site
    Santiago, 8420383, Chile
  • Research Site
    Temuco, 4810297, Chile
  • Research Site
    Viña del Mar, 2520612, Chile
  • Research Site
    Beijing, 100142, China
  • Research Site
    Changchun, 130000, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Oulu, FI-90029, Finland
  • Research Site
    Tampere, FI-33521, Finland
  • Research Site
    Athens, 115 22, Greece
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Athens, 14564, Greece
  • Research Site
    Heraklion, 71110, Greece
  • Research Site
    Holargos, Athens, 155 62, Greece
  • Research Site
    Ioannina, 45000, Greece
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    King's Park, 150001, Hong Kong
  • Research Site
    Shatin, 00000, Hong Kong
  • Research Site
    Ahmedabad, 380016, India
  • Research Site
    Bangalore, 560068, India
  • Research Site
    Bangalore, 560076, India
  • Research Site
    Chennai, 600035, India
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Karamsad, 388325, India
  • Research Site
    New Delhi, 110 085, India
  • Research Site
    Beersheba, 8410101, Israel
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Kfar Saba, 95847, Israel
  • Research Site
    Nahariya, 22100, Israel
  • Research Site
    Petah Tikva, 49100, Israel
  • Research Site
    Ramat Gan, 5265601, Israel
  • Research Site
    Bunkyō City, 160-0023, Japan
  • Research Site
    Fukushima, 960-1295, Japan
  • Research Site
    Habikino-shi, 583-8588, Japan
  • Research Site
    Hirosaki-shi, 036-8545, Japan
  • Research Site
    Iizuka-shi, 820-8505, Japan
  • Research Site
    Iwakuni-shi, 740-8510, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Kishiwada-shi, 596-8501, Japan
  • Research Site
    Kobe, 650-0047, Japan
  • Research Site
    Kurume-shi, 830-0011, Japan
  • Research Site
    Kyoto, 607-8062, Japan
  • Research Site
    Mitaka-shi, 181-8611, Japan
  • Research Site
    Nagaoka-shi, 940-2085, Japan

Showing the first 100 of 210 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cheng Y, Zhou Q, Han B, Fan Y, Shan L, Chang J, Sun S, Fang J, Chen Y, Sun J, Wu G, Mann H, Naicker K, Shire N, Mok T, de Castro G Jr. NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. Lung Cancer. 2023 Apr;178:87-95. doi: 10.1016/j.lungcan.2023.01.013. Epub 2023 Feb 1. PubMed 36806898 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Sep 2020, 58 months.

Results were first posted in May 2022, 1 year 8 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 58 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2015
First posted
Sep 7, 2015
StartActual
Nov 3, 2015
Primary completionActual
Sep 21, 2020
CompletionEst.
Dec 31, 2026
Results first posted
May 24, 2022
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02542293
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 7, 2015
Start date
Nov 3, 2015
Primary completion
Sep 21, 2020
Completion
Dec 31, 2026 (estimated)
Results posted
May 24, 2022
Last update
Aug 6, 2026

Study contacts

Gilberto de Castro
principal investigator · Faculdade de Medicina da Universidade de São Paulo

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion